A cholesterol edit, one year later

One infusion, a year of lower LDL cholesterol and triglycerides: that gets my attention. CTX310 turns off ANGPTL3 in the liver, and in the highest-dose group, LDL was down 52.5% and triglycerides 47.8% from baseline after 12 months. But the number I want beside those percentages is 15. That is the size of the entire first-in-human trial, not a population-wide outcome study. No therapy-related serious adverse events were reported through the first year; a 15-year safety follow-up is planned. Before we can say what this means for heart attacks, strokes, or routine care, we need larger studies, longer follow-up, and clinical outcomes. For now, this is a striking early lipid signal, not a treatment recommendation.